New drug tested to stop blood Cancer's return after risky transplant

This early-stage trial tested whether a drug called fedratinib could safely prevent cancer from returning in patients with certain blood cancers (myeloproliferative neoplasms) after they received a stem cell transplant. The study aimed to find the safest effective dose and see if the drug could help patients live longer without their disease getting worse. The trial was terminated early and involved a small group of 12 adult patients who had already undergone the transplant.